Storage devices use jet fuel to keep the right temperature for up to five days in the field.

The vaccine could now be used to help end the worst recorded outbreak of Ebola, which has infected about 28,000 people in Guinea, Sierra Leone and Liberia and killed more than 11,200 people in the West African countries since it began in December 2013.

The trial was called Ebola ça Suffit – French for “Ebola that’s enough”.

Though the vaccine has yet to be licensed, the trial ended randomization on July 26 so that all those at risk could receive the vaccine, while reducing the time needed to gather conclusive evidence for licensing purposes. The study results were published online Friday in the journal Lancet.

To create the vaccine, scientists removed a gene from another virus, vesicular stomatitis, and replaced it with an Ebola virus gene that can’t cause the disease alone.

Another WHO reform focus is on spearheading research and development work on vaccines, medications, and diagnostic tests, Chan said. At this stage however, there are no plans to vaccinate everyone prevenptively, as is the case for polio or measles, according to Merck. No placebos were administered.

Pharmaceutical giant Merck and NewLink Genetics, a biotech firm based in Ames, Iowa, are developing the rVSV-ZEBOV vaccine commercially.

Hailing the outcomes of the trial, the World Well being Group (WHO) stated the worldwide group is “on the verge of an efficient Ebola vaccine”, AFP reported. The other group, consisting of 3,500 people, were administered the drug after 10 days delay of coming in contact with the virus.

Given these results, trial sponsors have authorized all those at risk to get vaccinated immediately, said the WHO.

“These communities need an effective vaccine sooner rather than later”, Gavi’s chief executive Seth Berkley said. In injure in this, a trial vaccination was also analyzed on many folks in Guinea in contact with Ebola may seem like useful and can help shut off the continuing plague in West Africa.

UNMEER, the first-ever UN emergency health mission, was established on 19 September 2014 to meet immediate needs related to the unprecedented fight against Ebola.

And the cost of mass vaccination to cover all eventualities would be prohibitive.

The vaccine is administered via a shot to the upper arm.

“This will go down in history as one of those hallmark public health efforts”, says Michael Osterholm, the director of the Center for Infectious Disease Research and Policy in Twin Cities, Minnesota, who wasn’t involved in the study. They’re also still analyzing possible adverse reactions to the drug.

A unique clinical trial took place in Guinea. “So that means the best way we can secure continued access to the vaccine in Guinea is to continue the trial”, he told VOA. The gene for the outer protein of the VSV virus, which is incredibly rare in humans, is replaced with a segment of the gene from the Ebola Zaire species. He feels that although the vaccine is very helpful, people still think that it could end the outbreak alone.

Researchers in the Guinea trial say that the number of new clusters of potential patients is falling, because the rate of new diagnoses in the country has dropped.